Clinical Trial Update: S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating S-1 plus gefitinib versus gefitinib alone in EGFR-mutant advanced non-squamous non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gefitinib (Gefitinib)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Advanced NSCLC With EGFR Mutation | Phase 2 | Status: UNKNOWN